Supplementary Online Content

Xu JY, Wei XL, Ren C, et al. Association of plasma Epstein-Barr virus DNA with outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 immunotherapy. *JAMA Netw Open.* 2022;5(3):e220587. doi:10.1001/jamanetworkopen.2022.0587

eTable. The Correlation Between Baseline EBV DNA Titer and Clinical Factors
eFigure. Association of a Dynamic Change in EBV DNA Titer and Disease Status (Progression or Free From Progression)

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable.** The Correlation Between Baseline EBV DNA Titer and Clinical Factors

| Factors                        | EBV titer ≥10,000 IU/mL | EBV titer <10,000 IU/mL | P value |
|-------------------------------|-------------------------|-------------------------|---------|
| Sex                           |                         |                         | 0.2816  |
| Male                          | 89 (91.2%)              | 59 (80.6%)              |         |
| Female                        | 15 (8.8%)               | 16 (19.3%)              |         |
| Age (years)                   |                         |                         | 0.9799  |
| <46                           | 49 (47.1%)              | 36 (48.0%)              |         |
| ≥46                           | 55 (59.6%)              | 39 (40.6%)              |         |
| Line of prior therapy         |                         |                         | 0.8328  |
| 1 line                        | 50 (48.1%)              | 34 (45.3%)              |         |
| 2+ lines                      | 54 (51.9%)              | 41 (54.7%)              |         |
| ECOG                          |                         |                         | 0.7761  |
| 0                             | 38 (36.5%)              | 25 (15.5%)              |         |
| 1                             | 66 (63.5%)              | 50 (66.7%)              |         |
| Histology                     |                         |                         | 0.9906  |
| Nonkeratinizing               | 100 (96.2%)             | 73 (17.2%)              |         |
| Keratinizing                  | 4 (3.8%)                | 2 (2.7%)                |         |
| PD-L1 status *                |                         |                         | 0.3893  |
| Negative                      | 70 (70.7%)              | 56 (77.8%)              |         |
| Positive                      | 29 (29.3%)              | 16 (22.2%)              |         |
| TMB (mutation/Mb) *           |                         |                         |         |
| TMB < 0.95                    | 45 (46.9)               | 37 (54.4)               | 0.9969  |
| TMB≥0.95                      | 51 (53.1)               | 31 (45.6)               |         |

* Positive is defined as ≥1% of tumor cells expressing PD-L1 by SP142 immunohistochemistry staining. * The cutoff value is defined as the median value of TMB.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand 1; TMB, tumor mutational burden.
eFigure 1. Association of a Dynamic Change in EBV DNA Titer and Disease Status (Progression or Free From Progression). (A) Association of the EBV DNA titer dynamic change in patients with a best response of complete response or partial response with disease status. (B) Association of the EBV DNA titer dynamic change in patients with a best response of stable disease with disease status.